{
    "root": "406a07e3-a3f8-4fef-901e-021d00743c40",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Remifentanil Hydrochloride"
    },
    "value": "20250213",
    "ingredients": [
        {
            "name": "REMIFENTANIL HYDROCHLORIDE",
            "code": "5V444H5WIC"
        },
        {
            "name": "GLYCINE",
            "code": "TE7660XO1C"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        }
    ],
    "indications": "Remifentanil hydrochloride (HCl) for injection is indicated for intravenous (IV) administration:\n                  \n                     \n                        •As an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures.\n                     \n                        •For continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting.\n                     \n                        •As an analgesic component of monitored anesthesia care in adult patients.",
    "contraindications": "• Monitor patients closely for respiratory depression when initiating therapy and following dosage increases and adjust the dosage accordingly. ( 2.1 ) • Initial Dosage in Adults : See full prescribing information for recommended doses in adult patients. ( 2.2 , 2.3 ) • Initial Dosage in Pediatric Patients : See full prescribing information for recommended doses in pediatric patients. ( 2.2 ) • Geriatric Patients : The starting doses should be decreased by 50% in elderly patients (> 65 years). ( 2.6 )",
    "warningsAndPrecautions": "Remifentanil HCl for injection should be stored at 2° to 25°C (36° to 77°F). Remifentanil HCl for IV use is supplied as follows:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Product Code\n                              \n                           \n                           \n                              \n                                 Unit of Sale\n                              \n                           \n                           \n                              \n                                 Strength\n                              \n                           \n                           \n                              \n                                 Each\n                              \n                           \n                        \n                        \n                           \n                              PRX723103\n                           \n                           \n                              NDC 63323-723-06 Unit of 10\n                           \n                           \n                              1 mg per vial\n                           \n                           \n                              NDC 63323-723-043 mL Single Dose Vial\n                           \n                        \n                     \n                  \n                  Discard unused portion.\n                  The container closure is not made with natural rubber latex.\n                  The brand names mentioned in this document are the trademarks of their respective owners.\n                  \n                      PREMIERProRx® is a registered trademark of Premier Healthcare Alliance, L.P., used under license.\n                  Manufactured by:\n                     Fresenius Kabi\n                  \n                  Lake Zurich, IL 60047\n                  www.fresenius-kabi.com/us\n                  451651A",
    "adverseReactions": "Remifentanil HCl is contraindicated:\n                  \n                     \n                        •For epidural or intrathecal administration due to the presence of glycine in the formulation [see Nonclinical Toxicology (13)].\n                     \n                        •In patients with hypersensitivity to remifentanil (e.g., anaphylaxis) [see Adverse Reactions (6.2)]."
}